MedTrace Logo

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

NCT01664039 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2015-08-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.

Conditions

Interventions

DRUG

Travoprost 0.004% ophthalmic solution

Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative

DRUG

Bimatoprost 0.01% ophthalmic solution

Ophthalmic solution containing benzalkonium chloride (BAK)

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-06-30
Completion
2014-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01664039 on ClinicalTrials.gov